Administrative Core

项目摘要 该计划的目标是开发下一代通用冠状病毒合成核酸疫苗 利用核酸递送纳米颗粒的进展，将提供广泛的保护 多个季节性和新兴的外壳。已知有7种冠状病毒可感染人，4人(HCoV-NL63，- 229E、-OC43、-HKU1)和3种人畜共患病(SARS-CoV-1、SARS-CoV-1、SARS-CoV-1)。 CoV-2和MERS-CoV)。人畜共患冠状病毒是由动物的交叉传播事件和大多数 由于人们缺乏免疫力，人们对此感到担忧。未来相关病毒的传播令人担忧，新疫苗 迫切需要为人们提供针对多种冠状病毒的广泛保护的战略。 该项目汇集了来自Wistar研究所的团队(Weiner、Kulp和Patel博士)的专业知识， 宾夕法尼亚大学(奥尔曼博士)和印第安纳大学(帕勒森博士)。总而言之，团队已经 在病毒学、免疫学、蛋白质工程、分子和细胞生物化学方面有丰富经验。 该计划由2个研究项目组成，由行政核心(AC)监督。阿米·帕特尔博士 (维斯塔尔研究所)将担任AC主任。 行政核心(AC)的目标，由Patel博士领导，作为一个三人领导团队的一部分，包括 Kulp博士、Weiner和Patel将提供全面的治理和监督，以确保计划目标 相遇了。这些目标将通过包括行政和财务在内的积极计划管理来实现 支持、项目监测和报告、研究合规监督、团队沟通、资源 管理、冲突解决和知识产权管理。在这些职能中，交流将是 负责整个项目的绩效、人员、样品分配和动物运输的协调。 咨询委员会将安排定期的团队电话会议，进行公开数据讨论和时间表审查，并组织年度审查 开会。AC将安排项目主管、项目负责人和NIH项目办公室之间的通话 并为计划反馈提供年度进度报告，并促进发布调查结果和 科学会议出席率。

Project Summary The goal of this Program is to develop a next-generation, universal coronavirus synthetic nucleic acid vaccine employing advancements in nucleic acid delivery of nanoparticles that will provide broad protection against multiple seasonal and emerging CoV. There are seven CoV known to infect people, 4 human (HCoV-NL63, - 229E, -OC43, -HKU1) and 3 zoonotic that have crossed into humans in the past 20 years (SARS-CoV-1, SARS- CoV-2, and MERS-CoV). Zoonotic CoV are introduced by cross-transmission events from animals and the most concerning due to lack of immunity in people. Spread of future related viruses is of concern and new vaccine strategies are urgently needed that will provide broad protection in people against multiple coronaviruses. This program brings together the expertise of teams from The Wistar Institute (Drs. Weiner, Kulp, and Patel), The University of Pennsylvania (Dr. Allman), and Indiana University (Dr. Pallesen). Together, the team has significant experience in virology, immunology, protein engineering, and molecular and cellular biochemistry. The Program is organized into 2 Research Projects, overseen by the Administrative Core (AC). Dr. Ami Patel (The Wistar Institute) will serve as director for the AC. The goal of the Administrative core (AC), led by Dr. Patel as part of a three-member leadership team consisting of Dr. Kulp, Weiner and Patel, will provide overall governance and oversight to ensure the Program goals are met. These goals will be achieved through active program management including administrative and financial support, project monitoring and reporting, research compliance oversight, team communication, resource management, conflict resolution, and intellectual property management. In these functions, the AC will be responsible for overall program performance, personnel, sample distribution, and animal shipping coordination. The AC will arrange regular team calls for open data discussion and timeline review and organize yearly review meetings. The AC will arrange calls between the Program Direction, Project Leads and the NIH Program Office and provide yearly reports on progress for program feedback as well as facilitate publication of findings and scientific meeting attendance.